Bronnen:
Simuni T, on behalf of the Parkinson Study Group. A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results. AAN 2019.
Simuni T, on behalf of the Parkinson Study Group. A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results. AAN 2019.